Ua hoʻolaha ʻo EOFlow Co., Ltd., kahi mea hāʻawi i nā ʻōnaehana lawe lāʻau hiki ke hoʻohana ʻia, i kēia lā ua hoʻopaʻa inoa ʻo EOFlow Inc. i kahi ʻaelike e hoʻokumu i kahi ʻoihana hui ma US me ka UK biotech firm Zihipp Limited, kahi spin. mai ka Imperial College London.
ʻO ka hoʻokumu pono ʻana o nā analogues e hoʻomaikaʻi iā lākou no ka hāʻawi mau ʻana i ka subcutaneous no laila e ʻae i ka dosing lāʻau e hoʻohālikelike ʻia i ka metabolism o kahi mea maʻi, e wikiwiki ana i ka hoʻemi ʻana o ke kaumaha ʻoiai e pale ana i nā hopena ʻino mai ka overdosing. E hāʻawi ʻo EOFlow i kahi kālā mua a me kāna EOPatch hiki ke hoʻohana ʻia i ka lāʻau lapaʻau ʻoiai hāʻawi ʻo Zihipp i kāna mau peptide analogues proprietary a me ke kākoʻo lapaʻau no SanPlena. ʻO ka Luna Nui o EOFlow, ʻo Jesse J. Kim, e lawe i ke kuleana ma ke ʻano he Luna Nui o SanPlena aʻo ke koena o ka hui hoʻokō e hoʻopuni ʻia e nā limahana koʻikoʻi mai Zihipp a me EOFlow.
ʻO Zihipp kahi UK biotech firm i wili ʻia mai Imperial College London ma 2012. E alakaʻi ʻia e ka Prof. Sir Stephen R. Bloom i mahalo nui ʻia a me kahi hui noiʻi honua, hoʻomohala ka hui i nā hormones peptide e hakakā i ka piʻi nui o ka maʻi diabetes a me ka momona. ʻO Prof. Sir Stephen R. Bloom kekahi o nā loea obesity koʻikoʻi o ka honua a ua kālele kāna noiʻi ʻana i nā hormones ʻōpū e hoʻomalu i ka ʻai a me ka metabolism. Ua kaulana ʻo ia ma ke ʻano he kiʻi seminal i ka hoʻokumu ʻana i ka maʻi diabetes a me ka mākeke mālama momona. ʻO Professor Sir Stephen Bloom ke poʻo o ka Drug Development, Department of Metabolism, Digestion & Reproduction ma Imperial College London a me ka luna o ka noiʻi no North West London Pathology ma Imperial College Healthcare NHS Trust, e lawelawe ana i ʻeono mau haukapila koʻikoʻi.
Ua hoʻomohala ʻo Zihipp i kekahi mau moho lāʻau peptide hou i hoʻopaʻa ʻia no ka momona a me ka mālama ʻana i ka NASH (Non-Alcoholic Steatohepatitis) e like me ka hoʻopaʻa ʻana i ka ʻai e like me ka oxyntomodulin a me ka peptide YY i hōʻoia ʻia ma o nā hoʻokolohua lapaʻau. Ua hoʻopaʻa ʻia kēia mau analogues no ka hāʻawi ʻana i ka subcutaneous mau e pale aku i nā hopena ʻaoʻao maʻamau e pili ana i kēlā me kēia lā a i ʻole i kēlā me kēia pule i kēlā me kēia pule. Manaʻo ʻo SanPlena e hoʻohana i nā pono o ka EOFlow hiki ke hoʻohana ʻia, ka paepae mālama ola kino e hoʻokō ai i ka ʻōlelo hoʻohiki a kēia mau mea hana i ka hoʻokele wikiwiki a me ka nui o ka pohō kaumaha; a hiki i ka 15% o ke kaumaha o kekahi i loko o 2-3 mahina.
Wahi a ka World Health Organization (WHO) a me International Association for the Study of Obesity (IASO), i ka makahiki 2016, ʻoi aku ma mua o 1.9 biliona kanaka makua, 18 mau makahiki a ʻoi paha, ʻoi aku ka paona a ʻo kēia, 650 miliona (34%) ka momona. ʻO nā lāʻau lapaʻau o kēia manawa no ka momona i kaupalena ʻia e ke kumukūʻai, ka wikiwiki, ka pono a me ka hoʻomau. No ka laʻana, hiki i nā lāʻau lapaʻau i loaʻa no ka pohō kaumaha ke lawe ma mua o hoʻokahi makahiki e hana i 10-15% pohō kaumaha i hui pū ʻia me nā hopena ʻaoʻao o ka ʻōpū. Hāʻawi ke kahua hou ʻo SanPlena i kahi koi nui ʻole i hoʻokō ʻia no nā koho lapaʻau hou a hou no ka pohō kaumaha.
He aha e lawe ʻia mai kēia ʻatikala:
- Kim, will assume the role as the founding CEO of SanPlena while the rest of the executive team will be rounded out by senior staff from both Zihipp and EOFlow.
- has signed an agreement to establish a joint venture in the US with the UK biotech firm Zihipp Limited, a spin out from Imperial College London.
- Proprietary formulation of the analogues optimizes them for continuous subcutaneous delivery thus allowing the drug dosing to be tailored to a particular patient’s metabolism, speeding weight loss while avoiding adverse effects from over-dosing.
